About Merck Serono
Focusing our expertise to make a difference
At Merck Serono, we have an enduring commitment and focus in our core specialist therapeutic areas of oncology, neurodegenerative diseases, fertility and endocrinology, along with rheumatology as an emerging area of expertise. We also provide a portfolio of cardiometabolic care products, especially in emerging markets where patient need remains high.
Around the world, over 17,000 employees work to discover, develop, manufacture and commercialize our prescription medicines, available in over 150 countries. We are internationally recognized as a biotechnology leader, with innovative and successful products along with a well-stocked and promising development pipeline.
Each year we devote over 1 billion euros, or around 20% of total revenues, to discover and develop breakthrough solutions.
Our expertise in both biotechnology and pharmaceutical chemistry, combined with a profound understanding of disease in our focus therapeutic areas, enables us to take a flexible approach to finding the right compound to treat a specific disease. The capability to develop and manufacture new molecular entities of either type with equal success allows Merck Serono to exploit the full potential of the biological and chemical spheres at every stage of the drug development process.
We truly believe that our focused expertise can make a real difference to people living with serious diseases. Not everything we do leads to a breakthrough, but we never lose sight of the human need that motivates us.
Oncology – Erbitux®, UFT®
Merck Serono focuses on developing novel, cancer-specific therapies that provide beneficial therapeutic outcomes and create new options for cancer patients. Our monoclonal antibody, Erbitux, specifically blocks the epidermal growth factor receptor (EGFR) to enhance the effect of chemotherapy and radiotherapy.
Merck Serono focuses on developing novel, cancer-specific therapies that provide beneficial therapeutic outcomes and create new options for cancer patients. Our monoclonal antibody, Erbitux, specifically blocks the epidermal growth factor receptor (EGFR) to enhance the effect of chemotherapy and radiotherapy.
Neurodegenerative diseases – Rebif®
Merck Serono is a market leader in the treatment of multiple sclerosis (MS) with Rebif®, approved for the treatment of relapsing MS in over 80 countries worldwide.
Merck Serono is a market leader in the treatment of multiple sclerosis (MS) with Rebif®, approved for the treatment of relapsing MS in over 80 countries worldwide.
Fertility – GONAL-f®, Ovidrel, Luveris®, Cetrotide®, Crinone®, Pergoveris®
Merck Serono is the world leader in fertility treatment. We offer a full portfolio of fertility drugs for every stage of the reproductive cycle and recombinant versions of the three hormones needed to treat infertility, allowing physicians to tailor treatment to individual patient needs.
Merck Serono is the world leader in fertility treatment. We offer a full portfolio of fertility drugs for every stage of the reproductive cycle and recombinant versions of the three hormones needed to treat infertility, allowing physicians to tailor treatment to individual patient needs.
Endocrinology – Saizen®, Serostim®, Kuvan®, Egrifta™
Merck Serono was a pioneer in making recombinant human growth hormone available for the treatment of growth hormone deficiency in children and adults (Saizen) and for the treatment of HIV-associated wasting (Serostim). Today, our range of specialized therapies in this area includes Kuvan® (sapropterin dihydrochloride), the only drug indicated in Europe for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) in patients over the age of 4; or due to tetrahydrobiopterin BH4 deficiency. In the US, we offer EGRIFTA™ (tesamorelin for injection) as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy).
Merck Serono was a pioneer in making recombinant human growth hormone available for the treatment of growth hormone deficiency in children and adults (Saizen) and for the treatment of HIV-associated wasting (Serostim). Today, our range of specialized therapies in this area includes Kuvan® (sapropterin dihydrochloride), the only drug indicated in Europe for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU) in patients over the age of 4; or due to tetrahydrobiopterin BH4 deficiency. In the US, we offer EGRIFTA™ (tesamorelin for injection) as the first and only treatment indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy).
CardioMetabolic Care – Glucophage®, Concor®, Euthyrox®
Merck Serono offers an extensive range of therapeutic options for the integrated management of cardiovascular and metabolic diseases. These include the Glucophage franchise of oral antidiabetics for the treatment of type 2 diabetes, the beta-blocker bisoprolol (Concor) and a range of thyroid hormones (Euthyrox).
Merck Serono offers an extensive range of therapeutic options for the integrated management of cardiovascular and metabolic diseases. These include the Glucophage franchise of oral antidiabetics for the treatment of type 2 diabetes, the beta-blocker bisoprolol (Concor) and a range of thyroid hormones (Euthyrox).
